ITF 3756

Overview

ITF 3756 is a selective, orally active HDAC6 inhibitor. ITF 3756 antagonizes TNF-α-induced activation of the NF-κB pathway. ITF 3756 reduces PD-L1 expression on human monocytes and CD8 + T cells, and exhibits antitumor activity. ITF 3756 can be used in colon cancer-related research.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > NF-κB | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HDAC | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-156850
• CAS No.: 2247608-27-9
• Molecular Formula: C13H11N5O2S
• Molecular Weight: 301.32
• Purity: 98.55%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.08 mg/mL (6.90 mM); Clear solution
• Availability: In-stock

Source

Original product source